Global Soft Tissue Sarcoma Drugs 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI02254257

Publication Date:

February 27, 2025

Pages:

119

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Soft Tissue Sarcoma Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Soft Tissue Sarcoma Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Soft Tissue Sarcoma Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Soft Tissue Sarcoma Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Soft Tissue Sarcoma Drugs players cover Roche, Pfizer, Johnson & Johnson, GSK Plc, Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淪oft Tissue Sarcoma Drugs Industry Forecast鈥� looks at past sales and reviews total world Soft Tissue Sarcoma Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Soft Tissue Sarcoma Drugs sales for 2025 through 2031. With Soft Tissue Sarcoma Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Soft Tissue Sarcoma Drugs industry.
This Insight Report provides a comprehensive analysis of the global Soft Tissue Sarcoma Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Soft Tissue Sarcoma Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Soft Tissue Sarcoma Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Soft Tissue Sarcoma Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Soft Tissue Sarcoma Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Soft Tissue Sarcoma Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Local Sarcoma
Metastatic Sarcoma
Other Sarcoma
Segmentation by Application:
Hospitals
Oncology Centers
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Pfizer
Johnson & Johnson
GSK Plc
Teva Pharmaceuticals
Celgene
Bristol Myers Squibb
BeiGene
Shenzhen Chipscreen
Monopar Therapeutics
Akeso Biopharma

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Soft Tissue Sarcoma Drugs 麻豆原创 Size (2020-2031)
2.1.2 Soft Tissue Sarcoma Drugs 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Soft Tissue Sarcoma Drugs by Country/Region (2020, 2024 & 2031)
2.2 Soft Tissue Sarcoma Drugs Segment by Type
2.2.1 Local Sarcoma
2.2.2 Metastatic Sarcoma
2.2.3 Other Sarcoma
2.3 Soft Tissue Sarcoma Drugs 麻豆原创 Size by Type
2.3.1 Soft Tissue Sarcoma Drugs 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Soft Tissue Sarcoma Drugs 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Soft Tissue Sarcoma Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Oncology Centers
2.4.3 Other
2.5 Soft Tissue Sarcoma Drugs 麻豆原创 Size by Application
2.5.1 Soft Tissue Sarcoma Drugs 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Soft Tissue Sarcoma Drugs 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Soft Tissue Sarcoma Drugs 麻豆原创 Size by Player
3.1 Soft Tissue Sarcoma Drugs 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Soft Tissue Sarcoma Drugs Revenue by Player (2020-2025)
3.1.2 Global Soft Tissue Sarcoma Drugs Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Soft Tissue Sarcoma Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Soft Tissue Sarcoma Drugs by Region
4.1 Soft Tissue Sarcoma Drugs 麻豆原创 Size by Region (2020-2025)
4.2 Global Soft Tissue Sarcoma Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Soft Tissue Sarcoma Drugs 麻豆原创 Size Growth (2020-2025)
4.4 APAC Soft Tissue Sarcoma Drugs 麻豆原创 Size Growth (2020-2025)
4.5 Europe Soft Tissue Sarcoma Drugs 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Soft Tissue Sarcoma Drugs 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Soft Tissue Sarcoma Drugs 麻豆原创 Size by Country (2020-2025)
5.2 Americas Soft Tissue Sarcoma Drugs 麻豆原创 Size by Type (2020-2025)
5.3 Americas Soft Tissue Sarcoma Drugs 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Soft Tissue Sarcoma Drugs 麻豆原创 Size by Region (2020-2025)
6.2 APAC Soft Tissue Sarcoma Drugs 麻豆原创 Size by Type (2020-2025)
6.3 APAC Soft Tissue Sarcoma Drugs 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Soft Tissue Sarcoma Drugs 麻豆原创 Size by Country (2020-2025)
7.2 Europe Soft Tissue Sarcoma Drugs 麻豆原创 Size by Type (2020-2025)
7.3 Europe Soft Tissue Sarcoma Drugs 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Soft Tissue Sarcoma Drugs by Region (2020-2025)
8.2 Middle East & Africa Soft Tissue Sarcoma Drugs 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Soft Tissue Sarcoma Drugs 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Soft Tissue Sarcoma Drugs 麻豆原创 Forecast
10.1 Global Soft Tissue Sarcoma Drugs Forecast by Region (2026-2031)
10.1.1 Global Soft Tissue Sarcoma Drugs Forecast by Region (2026-2031)
10.1.2 Americas Soft Tissue Sarcoma Drugs Forecast
10.1.3 APAC Soft Tissue Sarcoma Drugs Forecast
10.1.4 Europe Soft Tissue Sarcoma Drugs Forecast
10.1.5 Middle East & Africa Soft Tissue Sarcoma Drugs Forecast
10.2 Americas Soft Tissue Sarcoma Drugs Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.2.2 Canada 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.2.3 Mexico 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.2.4 Brazil 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.3 APAC Soft Tissue Sarcoma Drugs Forecast by Region (2026-2031)
10.3.1 China Soft Tissue Sarcoma Drugs 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.3.3 Korea 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.3.4 Southeast Asia 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.3.5 India 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.3.6 Australia 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.4 Europe Soft Tissue Sarcoma Drugs Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.4.2 France 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.4.3 UK 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.4.4 Italy 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.4.5 Russia 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.5 Middle East & Africa Soft Tissue Sarcoma Drugs Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.5.2 South Africa 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.5.3 Israel 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.5.4 Turkey 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
10.6 Global Soft Tissue Sarcoma Drugs Forecast by Type (2026-2031)
10.7 Global Soft Tissue Sarcoma Drugs Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Soft Tissue Sarcoma Drugs Forecast
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Soft Tissue Sarcoma Drugs Product Offered
11.1.3 Roche Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Soft Tissue Sarcoma Drugs Product Offered
11.2.3 Pfizer Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Information
11.3.2 Johnson & Johnson Soft Tissue Sarcoma Drugs Product Offered
11.3.3 Johnson & Johnson Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Johnson & Johnson Main Business Overview
11.3.5 Johnson & Johnson Latest Developments
11.4 GSK Plc
11.4.1 GSK Plc Company Information
11.4.2 GSK Plc Soft Tissue Sarcoma Drugs Product Offered
11.4.3 GSK Plc Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 GSK Plc Main Business Overview
11.4.5 GSK Plc Latest Developments
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Information
11.5.2 Teva Pharmaceuticals Soft Tissue Sarcoma Drugs Product Offered
11.5.3 Teva Pharmaceuticals Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Teva Pharmaceuticals Main Business Overview
11.5.5 Teva Pharmaceuticals Latest Developments
11.6 Celgene
11.6.1 Celgene Company Information
11.6.2 Celgene Soft Tissue Sarcoma Drugs Product Offered
11.6.3 Celgene Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Celgene Main Business Overview
11.6.5 Celgene Latest Developments
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Company Information
11.7.2 Bristol Myers Squibb Soft Tissue Sarcoma Drugs Product Offered
11.7.3 Bristol Myers Squibb Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Bristol Myers Squibb Main Business Overview
11.7.5 Bristol Myers Squibb Latest Developments
11.8 BeiGene
11.8.1 BeiGene Company Information
11.8.2 BeiGene Soft Tissue Sarcoma Drugs Product Offered
11.8.3 BeiGene Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 BeiGene Main Business Overview
11.8.5 BeiGene Latest Developments
11.9 Shenzhen Chipscreen
11.9.1 Shenzhen Chipscreen Company Information
11.9.2 Shenzhen Chipscreen Soft Tissue Sarcoma Drugs Product Offered
11.9.3 Shenzhen Chipscreen Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Shenzhen Chipscreen Main Business Overview
11.9.5 Shenzhen Chipscreen Latest Developments
11.10 Monopar Therapeutics
11.10.1 Monopar Therapeutics Company Information
11.10.2 Monopar Therapeutics Soft Tissue Sarcoma Drugs Product Offered
11.10.3 Monopar Therapeutics Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Monopar Therapeutics Main Business Overview
11.10.5 Monopar Therapeutics Latest Developments
11.11 Akeso Biopharma
11.11.1 Akeso Biopharma Company Information
11.11.2 Akeso Biopharma Soft Tissue Sarcoma Drugs Product Offered
11.11.3 Akeso Biopharma Soft Tissue Sarcoma Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Akeso Biopharma Main Business Overview
11.11.5 Akeso Biopharma Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.